HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population
NCT ID: NCT03916432
Last Updated: 2019-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
3000 participants
INTERVENTIONAL
2018-12-01
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment
NCT01880879
Brazil Xience V Everolimus-Eluting Coronary Stent System "Real-World" Outcomes Registry
NCT00989066
RESOLUTE ONYX China RCT Study
NCT03466151
Xience/Promus for Long Coronary Lesion Registry
NCT01147237
Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents
NCT01443104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional group
HELIOS biodegradable polymer sirolimus-eluting stents
HELIOS biodegradable polymer sirolimus-eluting stents
HELIOS biodegradable polymer sirolimus-eluting stents
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HELIOS biodegradable polymer sirolimus-eluting stents
HELIOS biodegradable polymer sirolimus-eluting stents
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;
3. Patients are, in the opinion of the investigator, unable to comply with the requirements of the study protocol
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Luhe Hospital
OTHER
Cangzhou People's Hospital
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
First Affiliated Hospital of Shantou University Medical College
OTHER
Western Central Hospital of Hainan Province
UNKNOWN
Second Affiliated Hospital of Hainan Medical College
UNKNOWN
Huizhou Municipal Central Hospital
OTHER
First People's Hospital of Yulin
OTHER
Shaanxi Armed Police Corps Hospital
UNKNOWN
Xi'an No.3 Hospital
OTHER_GOV
Tang-Du Hospital
OTHER
Ankang Central Hospital
OTHER
General Hospital of Ningxia Medical University
OTHER
Cardiovascular Hospital of Ningxia Medical University
UNKNOWN
First Affiliated Hospital of Xinjiang Medical University
OTHER
Kaifeng Central Hospital
OTHER
Xinyang Central Hospital
OTHER
People's Hospital of Zhengzhou University
OTHER
Zhoupu Hospital, Pudong New Area, Shanghai
UNKNOWN
Shanghai Longhua Hospital
UNKNOWN
Huangshan Shoukang Hospital
UNKNOWN
First Affiliated Hospital of Southern Anhui Medical College
UNKNOWN
First Affiliated Hospital of Harbin Medical University
OTHER
Harbin Medical University
OTHER
Third Affiliated Hospital of Qiqihar
UNKNOWN
First Affiliated Hospital of Jiamusi
UNKNOWN
Harbin First Hospital
UNKNOWN
The Second Hospital of Shenyang Medical College
OTHER
Yingkou Central Hospital
UNKNOWN
Xijing Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ling Tao, MD, PhD
Role: STUDY_DIRECTOR
First Affiliated Hospital，Fourth Military Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ling Tao
Xi’an, Shanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Yuan F, Chen X, Song X, Wang D, Zhang Z, Li W, Li Z, Li H, Chen X, Huo Y, Wang L, Lu C, Lu Q, Xu B, Li W, Lyu S; HOPE Investigator. Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial. Chin Med J (Engl). 2014;127(14):2561-6.
Zheng B, Liu Y, Zhang R, Yang W, Su F, Wang R, Chen D, Shen G, Qiu Y, Wang L, Chen C, Wu Z, Li F, Li J, Li C, Gao C, Tao L; HELIOS Investigators. A novel biodegradable polymer-coated sirolimus-eluting stent: 1-year results of the HELIOS registry. Chin Med J (Engl). 2023 Aug 5;136(15):1848-1854. doi: 10.1097/CM9.0000000000002324.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ky20182050-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.